Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01077154
Recruitment Status : Terminated (Terminated: Amgen decision following Primary Analysis. Not due to safety reason)
First Posted : February 26, 2010
Last Update Posted : April 24, 2018
Daiichi Sankyo, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : August 31, 2017
  Actual Study Completion Date : March 26, 2018